menu
    • menu

    Company profile for Aspen Pharmacare Holdings

    Aspen API-PSE
    News
    Proposed Divestment of Aspen Asia Pacific for R26.5 billion

    29 Dec 2025

    // PRESS RELEASE

    Stephen Saad receives both AABLA Lifetime Achievement Award

    13 Nov 2025

    // PRESS RELEASE

    Aspen Highlights Rising Diabetes Disease Burden

    13 Nov 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Aspen API

    Contact Supplier

    Website

    BIO Partnering at JPM

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    radio-compass-blog/top-news-of-2025-drugmakers-invest-in-us-capacities-agree-to-lower-medicaid-prices-pfizer-buys-obesity-focused-biotech-metsera

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. Aspen is represented in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, France, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States of America. Acquisitions announced in 2013 will further extend the Group’s emerging market presence to the Commonwealth of Independent States, comprising Russia and the former Soviet Republics.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aspen Pharmacare HoldingsSouthAfrica Flag
    Country
    Country
    South Africa
    Address
    Address
    Aspen House, Aspen Park 98 Armstrong Avenue La Lucia Ridge, Durban
    Telephone
    Telephone
    +27 315808600
    Client Email
    Email
    jkemmeren@nl.aspenpharma.com
    Client Website
    Website
    https://www.aspenpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aspen-pharmacare-global/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/aspenpharma
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

    US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

    The pharmaceutical industry in the United States continued to grapple with drug shortages during the first quarter (Q1) of 2025. According to the American Society of Health‑System Pharmacists (ASHP), the total number of active shortages stood at 270 as of March 31, 2025 — only slightly below the 277 reported in September 2024, but down 16.4 percent from an all‑time high of 323 reported in Q1 2024.These numbers imply that while dramatic surges in drug shortages may have subsided, underlying vulnerabilities in manufacturing, supply chains, and raw‑material sourcing continue to frustrate efforts towards a durable resolution.A deeper analysis of these drug scarcities reveals that 41 percent of the 270 active shortages first emerged in 2022 or earlier. This implies that many of the current disruptions have become chronic in nature and are exerting pressure on pharmacy operations. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available)CNS drugs dominate with 49 meds in short supply; antimicrobials face shortage of 39 drugsClass‑specific analysis reveals that central nervous system (CNS) agents remained the most disrupted category, with 49 distinct CNS drugs having faced scarcities during Q1. This group spans anxiolytics (anti-anxiety drugs) such as clonazepam and flurazepam, sedatives like lorazepam and midazolam, and stimulants such as methylphenidate and lisdexamfetamine. These shortages pose two challenges — controlling seizures and managing sedation in acute care settings. After CNS agents, antimicrobials was the second‑largest category, with shortages affecting 39 drugs. Key antibacterial and anti-fungal agents such as cefotaxime sodium powder for injection, clindamycin phosphate, rifampin, and metronidazole find themselves on ASHP’s active‑shortage roster, threatening both routine hospital protocols and emergency sepsis management.Fluids and electrolytes occupied the third spot, with 29 items facing shortage in Q1 2025. Hormone agents, including insulin analogs, ranked fourth with 24 drugs in short supply.Chemotherapy medications rounded out the top five categories, with 23 antineoplastic agents (a broad class of medications used to treat cancer) flagged as actively constrained in Q1 2025. Notable shortages included azacitidine, carboplatin, methotrexate, and streptozocin. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) US faces 26 new shortages; Pharmacopeia list warns of 100 vulnerable medicationsThe first quarter saw the emergence of 26 new shortage declarations, emphasizing that even drugs previously deemed reliably sourced can fall into scarcity. The US has been facing a shortage of attention deficit hyperactivity disorder (ADHD) drugs since 2022. The new shortages included ADHD transdermal patch methylphenidate, peginterferon alfa‑2a (Pegasys) used in chronic hepatitis B and C, and bacitracin ophthalmic ointment.The fragility of the pharmaceutical supply chains has been particularly evident in the aftermath of natural disasters. Hurricane Helene’s flooding at Baxter’s Marion, North Carolina, facility deeply affected IV‑solution supply lines. Baxter supplies roughly 60 percent of the US’ IV fluids and the ASHP report listed “hurricane” as the reason behind nine percent of drug shortages, as of January 2025.Regulatory and policy interventions continue to evolve. The US Pharmacopeia’s inaugural Vulnerable Medicines List, launched in 2025, identifies 100 drugs at the highest risk of future shortages, with a particular focus on injectables (comprising 71 percent of the list) and essential hospital care.Antibiotics, medications for pain management and oncology are the other drugs on the list. Although 61 percent of these vulnerable medicines were not in active shortage at the time of listing, their inclusion is intended to galvanize manufacturers and purchasing organizations to bolster inventories.Meanwhile, the Government Accountability Office in the US has called on the Department of Health and Human Services (HHS) to establish a formal coordination mechanism, warning that elimination of the HHS supply‑chain coordinator role in May 2025 risks fragmenting federal response efforts. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Global shortages mirror US patterns; Europe launches monitoring platform Globally, we notice comparable trends. For instance, Europe has rolled out the European Shortages Monitoring Platform (ESMP) this year in order to centralize shortage reporting across member states. Critical‑medicine shortages in the EU — in areas such as oncology, ADHD, and critical care analgesics — mirror US patterns. The European Medicines Agency’s shortage list currently holds 37 human drugs.According to Health Canada’s May 12, 2025 update, its Tier 3 list had 18 drug shortages that are considered to have the greatest impact on Canada’s drug supply and health‑care system. Tier 3 designation is based on medical necessity and minimal availability of alternatives.In hematology and oncology, scarcity of essential drugs like Oncaspar for acute lymphoblastic leukemia, idarubicin and lomustine for leukemias and brain tumors, anagrelide for thrombocythemia, and preservative‑free methotrexate for various malignancies underscore the impact these drug shortages can have on treatment. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Our viewThe global pharma supply chain is dealing with a fresh wave of uncertainties, especially with the likelihood of tariffs on drugs imported into the US. Analysts warn that the proposed pharmaceutical tariffs could exacerbate supply issues.Over 50 percent of drugs used in the US are manufactured abroad. Generic sterile injectable drugs — like chemotherapy medications and IV saline — are particularly vulnerable due to their complex manufacturing processes and low profit margins. Generic drugs (which account for 90 percent of prescriptions filled in the US) could face increased pressure, as many rely on raw materials from China and India. This could result in more severe drug shortages in the future. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4125

    https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities

    #PharmaFlow by PHARMACOMPASS
    22 May 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Proposed Divestment of Aspen Asia Pacific for R26.5 billion
    Proposed Divestment of Aspen Asia Pacific for R26.5 billion

    29 Dec 2025

    // PRESS RELEASE

    https://www.aspenpharma.com/proposed-divestment-of-aspen-asia-pacific-excluding-china-for-r26-5-billion/

    PRESS RELEASE
    29 Dec 2025
    Share Share
    Stephen Saad receives both AABLA Lifetime Achievement Award
    Stephen Saad receives both AABLA Lifetime Achievement Award

    13 Nov 2025

    // PRESS RELEASE

    https://www.aspenpharma.com/stephen-saad-aabla-2025/

    PRESS RELEASE
    13 Nov 2025
    Share Share
    Aspen Highlights Rising Diabetes Disease Burden
    Aspen Highlights Rising Diabetes Disease Burden

    13 Nov 2025

    // PRESS RELEASE

    https://www.aspenpharma.com/aspen-wdd-2025/

    PRESS RELEASE
    13 Nov 2025
    Share Share
    Aspen Wins Approval to Market Lilly's Mounjaro in South Africa
    Aspen Wins Approval to Market Lilly's Mounjaro in South Africa

    13 Oct 2025

    // REUTERS

    https://www.reuters.com/sustainability/boards-policy-regulation/aspen-wins-approval-market-lillys-mounjaro-weight-loss-south-africa-2025-10-13/

    REUTERS
    13 Oct 2025
    Share Share
    Aspen Aims for Profit Turnaround with Insulin, GLP-1 Drugs
    Aspen Aims for Profit Turnaround with Insulin, GLP-1 Drugs

    04 Sep 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/south-africas-aspen-aims-profit-turnaround-with-insulin-glp-1-drugs-2025-09-03/

    REUTERS
    04 Sep 2025
    Share Share
    Aspen building momentum in Commercial Pharma & Manufacturing
    Aspen building momentum in Commercial Pharma & Manufacturing

    03 Sep 2025

    // PRESS RELEASE

    https://www.aspenpharma.com/aspen-building-momentum-in-commercial-pharmaceuticals-and-manufacturing-strategy-modified/

    PRESS RELEASE
    03 Sep 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aspen Announces Local Availability of Lilly’s Mounjaro

    Details:

    Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.


    Lead Product(s): Tirzepatide

    Therapeutic Area: Endocrinology Brand Name: Mounjaro

    Study Phase: Approved FDFProduct Type: Peptide, Unconjugated

    Sponsor: Eli Lilly

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 20, 2024

    Aspen API Comapny Banner

    01

    Aspen Pharmacare Holdings

    South Africa
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tirzepatide

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Eli Lilly

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aspen Announces Local Availability of Lilly’s Mounjaro

    Details : Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.

    Product Name : Mounjaro

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    December 20, 2024

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aspen Concludes Two Significant Agreements with Sandoz for China and Europe

    Details:

    The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.


    Lead Product(s): Octreotide Acetate

    Therapeutic Area: Endocrinology Brand Name: Sandostatin LAR Depot

    Study Phase: Approved FDFProduct Type: Peptide, Unconjugated

    Recipient: Sandoz B2B

    Deal Size: $99.9 million Upfront Cash: Undisclosed

    Deal Type: Agreement December 04, 2023

    Aspen API Comapny Banner

    02

    Aspen Pharmacare Holdings

    South Africa
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Octreotide Acetate

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved FDF

    Recipient : Sandoz B2B

    Deal Size : $99.9 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Aspen Concludes Two Significant Agreements with Sandoz for China and Europe

    Details : The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

    Product Name : Sandostatin LAR Depot

    Product Type : Peptide, Unconjugated

    Upfront Cash : Undisclosed

    December 04, 2023

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aspen, CEPI And The Bill & Melinda Gates Foundation Expand Commitments To Improve Access To Vaccines In Africa

    Details:

    PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.


    Lead Product(s): Pneumococcal Polysaccharide Conjugate Vaccine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Pneumosil

    Study Phase: Approved FDFProduct Type: Vaccine

    Sponsor: Gates Foundation

    Deal Size: $30.0 million Upfront Cash: Undisclosed

    Deal Type: Funding December 12, 2022

    Aspen API Comapny Banner

    03

    Aspen Pharmacare Holdings

    South Africa
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pneumococcal Polysaccharide Conjugate Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Gates Foundation

    Deal Size : $30.0 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Aspen, CEPI And The Bill & Melinda Gates Foundation Expand Commitments To Improve Access To Vaccin...

    Details : PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.

    Product Name : Pneumosil

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    December 12, 2022

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aspen Concludes a Collaboration Agreement to Manufacture and Make Available Four Aspen-Branded Vaccines for Africa

    Details:

    PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.


    Lead Product(s): 10-Valent Pneumococcal Polysaccharide Conjugate Vaccine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Approved FDFProduct Type: Vaccine

    Sponsor: Serum Institute of India

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration August 31, 2022

    Aspen API Comapny Banner

    04

    Aspen Pharmacare Holdings

    South Africa
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 10-Valent Pneumococcal Polysaccharide Conjugate Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Serum Institute of India

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Aspen Concludes a Collaboration Agreement to Manufacture and Make Available Four Aspen-Branded Vac...

    Details : PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countrie...

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    August 31, 2022

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Australia Registers First Eye Drops to Slow Short-sightedness Progress in Children

    Details:

    EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.


    Lead Product(s): Atropine Sulfate

    Therapeutic Area: Ophthalmology Brand Name: Eikance

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 18, 2022

    Aspen API Comapny Banner

    05

    Aspen Pharmacare Holdings

    South Africa
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Australia Registers First Eye Drops to Slow Short-sightedness Progress in Children

    Details : EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.

    Product Name : Eikance

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 18, 2022

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar® In South Africa

    Details:

    Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer patients in this region.


    Lead Product(s): Triptorelin Pamoate

    Therapeutic Area: Oncology Brand Name: Trelstar

    Study Phase: Approved FDFProduct Type: Hormone

    Sponsor: Debiopharm

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership February 01, 2022

    Aspen API Comapny Banner

    06

    Aspen Pharmacare Holdings

    South Africa
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Triptorelin Pamoate

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Debiopharm

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar® In South Africa

    Details : Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer pat...

    Product Name : Trelstar

    Product Type : Hormone

    Upfront Cash : Undisclosed

    February 01, 2022

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage

    Details:

    The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.


    Lead Product(s): Ad26.COV2.S

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Approved FDFProduct Type: Vaccine

    Sponsor: Johnson & Johnson

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement November 30, 2021

    Aspen API Comapny Banner

    07

    Aspen Pharmacare Holdings

    South Africa
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ad26.COV2.S

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Johnson & Johnson

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage

    Details : The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    November 30, 2021

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acino Acquires Selected Aspen Brands in South Africa

    Details:

    The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.


    Lead Product(s): Esomeprazole Magnesium

    Therapeutic Area: Gastroenterology Brand Name: Trustan

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Acino Pharma

    Deal Size: $119.4 million Upfront Cash: Undisclosed

    Deal Type: Acquisition October 22, 2021

    Aspen API Comapny Banner

    08

    Aspen Pharmacare Holdings

    South Africa
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esomeprazole Magnesium

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Acino Pharma

    Deal Size : $119.4 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Acino Acquires Selected Aspen Brands in South Africa

    Details : The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.

    Product Name : Trustan

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    October 22, 2021

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals

    Details:

    Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy due to menopause.


    Lead Product(s): Conjugated Estrogens

    Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Cenestin

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Avion Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership November 12, 2020

    Aspen API Comapny Banner

    09

    Aspen Pharmacare Holdings

    South Africa
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Conjugated Estrogens

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Avion Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals

    Details : Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy d...

    Product Name : Cenestin

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    November 12, 2020

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Divestment of Aspen’s European Thrombosis Business to Mylan and Withdrawal of Cautionary

    Details:

    Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.


    Lead Product(s): Fondaparinux Sodium

    Therapeutic Area: Hematology Brand Name: Arixtra

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Viatris

    Deal Size: $757.2 million Upfront Cash: $310.4 million

    Deal Type: Acquisition September 08, 2020

    Aspen API Comapny Banner

    10

    Aspen Pharmacare Holdings

    South Africa
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fondaparinux Sodium

    Therapeutic Area : Hematology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Viatris

    Deal Size : $757.2 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Divestment of Aspen’s European Thrombosis Business to Mylan and Withdrawal of Cautionary

    Details : Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.

    Product Name : Arixtra

    Product Type : Miscellaneous

    Upfront Cash : $310.4 million

    September 08, 2020

    Aspen API Comapny Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    01

    Brand Name : ORGARAN

    South Africa
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    DANAPAROID SODIUM

    Aspen Pharmacare Holdings

    Dosage Form : INJECTABLE; INJECTION

    Proprietary Name : ORGARAN

    Dosage Strength : 750 UNITS/0.6ML

    Approval Date : 1996-12-24

    Application Number : 20430

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : CYCLESSA

    South Africa
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code : AB

    DESOGESTREL; ETHINYL ESTRADIOL

    Aspen Pharmacare Holdings

    Dosage Form : TABLET; ORAL-28

    Proprietary Name : CYCLESSA

    Dosage Strength : 0.1MG,0.125MG,0.15MG;0.0...

    Approval Date : 2000-12-20

    Application Number : 21090

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code : AB

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : HEXADROL

    South Africa
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    DEXAMETHASONE

    Aspen Pharmacare Holdings

    Dosage Form : ELIXIR; ORAL

    Proprietary Name : HEXADROL

    Dosage Strength : 0.5MG/5ML

    Approval Date : 1982-01-01

    Application Number : 12674

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : HEXADROL

    South Africa
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    DEXAMETHASONE

    Aspen Pharmacare Holdings

    Dosage Form : TABLET; ORAL

    Proprietary Name : HEXADROL

    Dosage Strength : 0.5MG

    Approval Date : 1982-01-01

    Application Number : 12675

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : HEXADROL

    South Africa
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    DEXAMETHASONE

    Aspen Pharmacare Holdings

    Dosage Form : TABLET; ORAL

    Proprietary Name : HEXADROL

    Dosage Strength : 0.75MG

    Approval Date : 1982-01-01

    Application Number : 12675

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : HEXADROL

    South Africa
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    DEXAMETHASONE

    Aspen Pharmacare Holdings

    Dosage Form : TABLET; ORAL

    Proprietary Name : HEXADROL

    Dosage Strength : 1.5MG

    Approval Date : 1982-01-01

    Application Number : 12675

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : HEXADROL

    South Africa
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    DEXAMETHASONE

    Aspen Pharmacare Holdings

    Dosage Form : TABLET; ORAL

    Proprietary Name : HEXADROL

    Dosage Strength : 4MG

    Approval Date : 1982-01-01

    Application Number : 12675

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : HEXADROL

    South Africa
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code :

    DEXAMETHASONE SODIUM PHOSPHATE

    Aspen Pharmacare Holdings

    Dosage Form : INJECTABLE; INJECTION

    Proprietary Name : HEXADROL

    Dosage Strength : EQ 4MG PHOSPHATE/ML **Fe...

    Approval Date : 1982-01-01

    Application Number : 14694

    RX/OTC/DISCN : DISCN

    RLD : Yes

    TE Code :

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : HEXADROL

    South Africa
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code :

    DEXAMETHASONE SODIUM PHOSPHATE

    Aspen Pharmacare Holdings

    Dosage Form : INJECTABLE; INJECTION

    Proprietary Name : HEXADROL

    Dosage Strength : EQ 10MG PHOSPHATE/ML **F...

    Approval Date : 1982-01-01

    Application Number : 14694

    RX/OTC/DISCN : DISCN

    RLD : Yes

    TE Code :

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : HEXADROL

    South Africa
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    DEXAMETHASONE SODIUM PHOSPHATE

    Aspen Pharmacare Holdings

    Dosage Form : INJECTABLE; INJECTION

    Proprietary Name : HEXADROL

    Dosage Strength : EQ 20MG PHOSPHATE/ML

    Approval Date : 1982-01-01

    Application Number : 14694

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    Aspen API Comapny Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search